Search

EU funding approved for TOLERATE

On April 1, the European Commission approved funding for the TOLERATE training network, proposed by a KU Leuven-led consortium including EHA.

Read more

ASCAT 2023

EHA joins forces with the British Society of Haematology (BSH) & Annual Academy of Sickle Cell and Thalassaemia Conference (ASCAT) in organizing the 18th Annual Sickle Cell & Thalassaemia Conference.

Read more

SWG Educational Activities

In 2021, the SWG on Multiple Myeloma contributed a major part of the ESMO-EHA guidelines for multiple myeloma. The rapid changes of the treatment landscape for this disease require an adaptation of the guidelines.

Read more

Does the patient with myelofibrosis feel better through Pacritinib?

Pacritinib is an oral next-generation multikinase inhibitor with specificity for JAK2 and FLT3 being evaluated to treat myelofibrosis in two Phase 3 trials.

Read more

EU Elections and Health Policy

HemAffairs Article #1 – June 2019

2019 will see significant changes within the European institutions.

Read more

How to apply for CBTH

TimelinesApplication CBTH 2025
Deadline: September 24, 2024 (15:00 CEST)

Notification
November 2024

How to apply?Download the signature letter template. Fill in the template and get it duly signed for upload into the online application platform.

Read more

Highlights from the SWG

The SWG:

Was involved with the European Medicines Agency (EMA) on shortages—as part of our policy and regulatory work
Participated in the EMA Healthcare Professionals Policy Officers' Group (HCP POG) review of the ‘Frailty and Older People: Considerations in Medicine Development and…

Read more

Genetic Predisposition to Blood Cancer (Rare diseases)

The objectives of the group are:

Share and extend clinical knowledge on the diagnosis and treatment of hematologic malignancies with germline predisposition.

Read more